|
|
Prepublished online as a Blood First Edition Paper on August 15, 2002; DOI 10.1182/blood-2001-12-0306.
Submitted December 21, 2001
Accepted July 4, 2002
Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease
James G Taylor, Delia C Tang, Sharon A Savage, Susan F Leitman, Seth I Heller, Graham R Serjeant, Griffin P Rodgers, and Stephen J Chanock*
Section on Genomic Variation, Pediatric Oncology Branch, National Cancer Institute - Advancted Technology Center, National Institutes of Health, Gaithersburg, MD, USA
Molecular and Clinical Hematology Branch, NIDDK, National Institutes of Health, Bethesda, MD, USA
Department of Transfusion Medicine, Clinical Center, National Insitutes of Health, Bethesda, MD, USA
MRC Laboratories, University of the West Indies, Kingston, Jamaica
* Corresponding author; email: sc83a{at}nih.gov.
Stroke is a major cause of morbidity and mortality in sickle cell (SS) disease. Genetic risk factors have been postulated to contribute to this clinical outcome. The human genome project has substantially increased the catalog of variations in genes, many of which could modify the risk for manifestations of disease outcome in a monogenic disease, namely SS. VCAM1 is a cell adhesion molecule postulated to play a critical role in the pathogenesis of SS disease. We identified a total of 33 single nucleotide polymorphisms (SNPs) by sequencing the entire coding region, 2134 base pairs upstream of the 5' end of the published cDNA, 217 base pairs downstream of the 3' end of the cDNA, and selected intronic regions of the VCAM1 locus. Allelic frequencies for selected SNPs were determined in a healthy population. Four non-synonymous coding, 2 synonymous coding, and 4 common promoter SNPs were subsequently analyzed in a genetic association study of clinically apparent stroke in SS disease conducted in a cohort derived from a single institution in Jamaica (51 symptomatic cases and 51 matched controls). Of the 10 candidate SNPs analyzed in this pilot study, the variant allele of the non-synonymous SNP, VCAM1 G1238C, may be associated with protection from stroke (OR 0.35, 95% CI 0.15-0.83, P=0.04). Further study is required to confirm the importance of this variant in VCAM1 as a clinically useful modifier of outcome in SS disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Q. Lan, L. Zhang, M. Shen, M. T. Smith, G. Li, R. Vermeulen, S. M. Rappaport, M. S. Forrest, R. B. Hayes, M. Linet, et al.
Polymorphisms in Cytokine and Cellular Adhesion Molecule Genes and Susceptibility to Hematotoxicity among Workers Exposed to Benzene
Cancer Res.,
October 15, 2005;
65(20):
9574 - 9581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hoppe, W. Klitz, S. Cheng, R. Apple, L. Steiner, L. Robles, T. Girard, E. Vichinsky, and L. Styles
Gene interactions and stroke risk in children with sickle cell anemia
Blood,
March 15, 2004;
103(6):
2391 - 2396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Buchanan, M. R. DeBaun, C. T. Quinn, and M. H. Steinberg
Sickle Cell Disease
Hematology,
January 1, 2004;
2004(1):
35 - 47.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
